Defining and measuring recovery from ME/CFS: a physician perspective
Recovery from ME/CFS is one of the most contested concepts in the condition's clinical history. It has been claimed as achievable by proponents of graded exercise and cognitive behavioral therapy, rejected as misleading by patient advocates documenting long-term disability, and defined in widely varying ways by researchers comparing treatment arms. What it actually looks like — from the perspective of physicians who see these patients over years — was the subject of a 2018 qualitative study by Devendorf and colleagues in Quality of Life Research. The answer they found is useful not because it is hopeful in an uncritical way but because it is accurate: recovery in ME/CFS is not a clean return to a pre-illness baseline. It is an individually defined, often partial, and chronically variable process that standard clinical measurement tools are not designed to capture.
What the Study Did: Asking Physicians How They Think About Recovery
Devendorf and colleagues conducted semi-structured qualitative interviews with physicians who had substantive clinical experience managing ME/CFS patients. The physicians were asked to describe how they conceptualized recovery, what they considered meaningful improvement, how they discussed recovery with their patients, and what endpoints they used to track progress over time. The study design was qualitative rather than quantitative — the goal was to understand the clinical reasoning and experience of practitioners engaged with the condition, not to measure outcomes in a controlled trial.
This approach captures something that controlled trials typically miss: the texture of how recovery actually looks in the clinic, for real patients seen over years, rather than how it is defined by outcome measures chosen for statistical tractability. Physicians who have watched ME/CFS patients navigate recovery over long periods develop a different understanding of what the trajectory looks like than researchers designing six-month trial endpoints. Devendorf and colleagues chose to document that understanding systematically.
The Findings: Recovery Is Personal, Incremental, and Rarely Complete
The physicians interviewed did not converge on a single threshold or biomarker for recovery. They did not describe a state where patients returned completely to pre-illness function and sustained that return. What they described instead was a process: functional improvement measured against a patient's own recent trajectory rather than against a pre-illness ideal, engagement with life activities at a level the patient found meaningful, and stabilization of the condition such that worsening cycles became less frequent or less severe.
Recovery was consistently framed as individually defined. What constitutes meaningful functional improvement for a patient who was previously bedbound is different from what constitutes improvement for a patient who had been moderately functional. Physicians did not apply a universal threshold. They asked what the patient's life looked like before, what it looks like now, and whether the trajectory is moving in a direction the patient finds livable. The direction of travel mattered as much as the current position.
Partial recovery was treated as genuinely meaningful. A patient who goes from bedbound to housebound, or from housebound to leaving the house several times a week, has made significant functional gains even if they remain substantially below a pre-illness baseline. The physicians in this study recognized and named those gains as meaningful progress rather than treating them as inadequate because they fell short of full recovery. This is a clinical stance that matters for how patients understand their own trajectories.
Why ME/CFS Recovery Does Not Follow the Acute Illness Model
The expectation that recovery means returning to a pre-illness baseline is borrowed from the acute illness model — the patient gets a treatable infection, receives appropriate treatment, and recovers to where they were before. This model does not describe chronic systemic disease, and it especially does not describe ME/CFS, where multiple physiological systems have been dysregulated over extended periods and where recovery involves not a single system healing but a gradual recalibration of autonomic, cardiovascular, metabolic, and neurological function simultaneously.
Recovery from ME/CFS is not a single event with a clear endpoint. It is a process with its own rate-limiting factors across multiple domains. The resting autonomic dysregulation documented in ME/CFS — elevated sympathetic tone, impaired heart rate variability, exaggerated orthostatic responses — does not normalize quickly. The physical deconditioning that accumulates during periods of severe functional limitation has its own recovery curve, and that recovery has to be managed carefully against the risk of post-exertional worsening. The social disruption — lost employment, strained relationships, years of medical encounters that produced little actionable guidance — adds a third domain that does not automatically resolve when physical symptoms improve.
Each of these domains recovers on its own timeline and at its own pace. Expecting them all to resolve simultaneously, or expecting a threshold moment at which the patient has "recovered," ignores the multi-system complexity of what needs to recalibrate. The physician interviews in the Devendorf study reflect an implicit understanding of this complexity — the physicians are not waiting for a single biomarker to cross a threshold. They are watching multiple domains improve, stall, and improve again, over years.
The Measurement Gap: What Clinical Trials Cannot See
The majority of outcome measures used in ME/CFS clinical trials — standard fatigue scales, quality of life questionnaires, functional capacity assessments — are designed around comparisons to population norms or to pre-trial baselines. They are not designed to capture the kind of individually-defined, direction-of-travel improvement that the physicians in this study described as clinically meaningful.
This creates a systematic gap between what researchers measure and what clinicians observe. An intervention that produces meaningful improvement in the quality of daily life for patients who were previously bedbound may not produce statistically significant change on a population-referenced fatigue scale, because the improvement moves them from severe to moderate rather than from abnormal to normal. The trial concludes the intervention didn't work. The clinician seeing the same patients knows something changed. The Devendorf paper provides qualitative evidence for this gap and names it explicitly: the measurement infrastructure for ME/CFS recovery research is not calibrated to the recovery trajectories that actually occur.
What This Means for Patients Evaluating Their Own Progress
If you have ME/CFS and are evaluating your own trajectory, the Devendorf findings offer a specific reframing. The relevant endpoint is not who you were before ME/CFS. It is what the trajectory looks like from where you are now. If you are doing things this month that you could not do last year, that is meaningful progress regardless of whether it returns you to your pre-illness baseline. If you are spending fewer days in severe crashes, that is meaningful progress. If you are able to maintain a level of activity that would have caused a crash six months ago, the threshold has shifted.
The physicians in this study did not tell their patients to wait until they felt fully recovered to count their progress. They engaged with partial recovery as genuinely significant. The momentum of improvement is clinically meaningful even when the destination remains incomplete. For a condition where full return to pre-illness baseline is not a common outcome in the short term, evaluating whether the trajectory is moving in the right direction — and what is currently limiting further progress — is a more useful clinical frame than holding all improvement against a standard of full restoration that may be years away, if it arrives at all.